A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) — MAVERICK-HCM

Non-obstructive Hypertrophic Cardiomyopathy Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

Status Completed

Clinical Trial Summary

This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2 target drug concentrations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cardiomyopathies
Cardiomyopathy, Hypertrophic
Hypertrophy
Non-obstructive Hypertrophic Cardiomyopathy

Clinical Trial Details

NCT number	NCT03442764
Study type	Interventional
Source	MyoKardia, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 30, 2018
Completion date	January 7, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03723655` - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM	Phase 2/Phase 3
Completed	`NCT04826185` - A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial	Phase 2
Completed	`NCT01631006` - Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy	N/A
Recruiting	`NCT05569382` - Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy	Phase 4